Search
Lowbush blueberry
go.drugbank.com/drugs/DB14229InvestigationalIngredient used in over-the-counter medications.
PF-08046052
go.drugbank.com/drugs/DB22647InvestigationalPF-08046052 is under investigation in clinical trial NCT05983133 (A Study of PF-08046052/SGN-EGFRd2 in Advanced Solid Tumors).
ATG-101
go.drugbank.com/drugs/DB17162InvestigationalATG-101 is a novel PD-L1/4-1BB bispecific antibody that was designed to block the binding of immunosuppressive PD-1/PD-L1 and conditionally induce 4-1BB stimulation, thus activating anti-tumor immune effectors
Synonyms: PD-L1/4-1BB bispecific antibodyGotistobart
go.drugbank.com/drugs/DB19100InvestigationalGotistobart is under investigation in clinical trial NCT05671510 (ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors).
PF-04418948
go.drugbank.com/drugs/DB12024InvestigationalPf 04418948 is under investigation in clinical trial NCT01002963 (A Study To Investigate The Safety And Toleration Of A Single Dose Of PF-04418948 In Healthy Volunteers).
Riboflavin
go.drugbank.com/drugs/DB00140ApprovedInvestigationalNutraceuticalVet approvedNutritional factor found in milk, eggs, malted barley, liver, kidney, heart, and leafy vegetables. The richest natural source is yeast. It occurs in the free form only in the retina of the eye, in whey, and in urine; its principal forms ...
Mixtures: Se-Tan PLUS, Virt-PnDL-alpha tocopheryl acetate
go.drugbank.com/drugs/DB14477ApprovedMixtures: PR Natal 430, PR Natal 400Atoltivimab
go.drugbank.com/drugs/DB15898ApprovedInvestigational[A221825, A221830] A recent large-scale study elucidated that both neutralizing and Fc-mediated functions of antibodies were important for therapeutic benefit in animal models of EBOV infection.
Corifollitropin alfa
go.drugbank.com/drugs/DB09066ApprovedInvestigationalIn July 2014, Merck announced the receipt of a Complete Response Letter (CRL) from the U.S. FDA for its New Drug Application for this drug.
Palladium Pd-103
go.drugbank.com/drugs/DB15016ExperimentalPalladium Pd-103 is under investigation in clinical trial NCT00247312 (Pd-103 Dose De-Escalation for Early Stage Prostate Cancer: A Prospective Randomized Trial).